Engineered immune cells take on tough bladder cancer
NCT ID NCT07492628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment for people with advanced bladder cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins on cancer cells. Participants will receive chemotherapy before the cell infusion to help the cells work better. The main goals are to check safety and see if the treatment can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can removing bladder tumors in one piece improve cancer outcomes?
- Can a new nucleotide analogue boost cancer treatment?
- Can an AI agent match expert urologists? a major test begins
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Can a hybrid surgical technique better remove large bladder tumors?